Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GBIO Stock Forecast 2025-2026
$5.33
Current Price
$35.91M
Market Cap
Buy 2
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to GBIO Price Targets
+106.4%
To High Target of $11.00
+87.6%
To Median Target of $10.00
+31.3%
To Low Target of $7.00
GBIO Price Momentum
0.0%
1 Week Change
+4.3%
1 Month Change
-59.0%
1 Year Change
-49.7%
Year-to-Date Change
-61.4%
From 52W High of $13.80
+77.7%
From 52W Low of $3.00
📊 TOP ANALYST CALLS
Did GBIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Generation Bio is one of their latest high-conviction picks.
Latest GBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, GBIO has a neutral consensus with a median price target of $10.00 (ranging from $7.00 to $11.00). The overall analyst rating is N/A (N/A/10). Currently trading at $5.33, the median forecast implies a 87.6% upside. This outlook is supported by 2 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Nierengarten at Wedbush, projecting a 106.4% upside. Conversely, the most conservative target is provided by David Nierengarten at Wedbush, suggesting a 31.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GBIO Analyst Ratings
2
Buy
3
Hold
0
Sell
GBIO Price Target Range
Low
$7.00
Average
$10.00
High
$11.00
Current: $5.33
Latest GBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 18, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $10.00 |
| Aug 13, 2025 | Needham | Gil Blum | Buy | Reiterates | $15.00 |
| Aug 13, 2025 | Wedbush | David Nierengarten | Neutral | Downgrade | $7.00 |
| May 8, 2025 | Needham | Gil Blum | Buy | Reiterates | $8.00 |
| Apr 10, 2025 | Needham | Gil Blum | Buy | Reiterates | $8.00 |
| Mar 17, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $9.00 |
| Mar 14, 2025 | Needham | Gil Blum | Buy | Reiterates | $8.00 |
| Mar 14, 2025 | Citizens Capital Markets | Silvan Tuerkcan | Market Perform | Reiterates | $N/A |
| Jan 8, 2025 | Needham | Gil Blum | Buy | Maintains | $8.00 |
| Oct 23, 2024 | Needham | Gil Blum | Buy | Reiterates | $10.00 |
| Aug 8, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $5.00 |
| Aug 8, 2024 | Needham | Gil Blum | Buy | Reiterates | $10.00 |
| May 14, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $5.00 |
| May 14, 2024 | Needham | Gil Blum | Buy | Reiterates | $10.00 |
| Apr 10, 2024 | Needham | Gil Blum | Buy | Reiterates | $10.00 |
| Mar 7, 2024 | Needham | Gil Blum | Buy | Maintains | $10.00 |
| Mar 7, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $5.00 |
| Nov 10, 2023 | Wedbush | David Nierengarten | Outperform | Maintains | $9.00 |
| Oct 23, 2023 | JMP Securities | Silvan Tuerkcan | Market Perform | Downgrade | $N/A |
| Oct 19, 2023 | TD Cowen | Yaron Werber | Market Perform | Downgrade | $N/A |
Generation Bio Co. (GBIO) Competitors
The following stocks are similar to Generation Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Generation Bio Co. (GBIO) Financial Data
Generation Bio Co. has a market capitalization of $35.91M with a P/E ratio of -0.3x. The company generates $15.27M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -78.9% quarter-over-quarter, while maintaining an operating margin of -2,020.0% and return on equity of -80.8%.
Valuation Metrics
Market Cap
$35.91M
Enterprise Value
$-28,286,788
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
2.3x
Growth & Margins
Revenue Growth (YoY)
-78.9%
Gross Margin
N/A
Operating Margin
-2,020.0%
Net Margin
0.0%
EPS Growth
-78.9%
Financial Health
Cash/Price Ratio
+249.5%
Current Ratio
4.4x
Debt/Equity
51.6x
ROE
-80.8%
ROA
-27.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Generation Bio Co. (GBIO) Business Model
About Generation Bio Co.
What They Do
Develops novel gene therapies using non-viral methods.
Business Model
Generation Bio Co. operates by leveraging its innovative non-viral delivery platform to develop gene therapies aimed at treating various genetic disorders. The company generates revenue through partnerships, funding, and potentially by commercializing its gene therapy products as they advance through clinical development.
Additional Information
Focused on genetic and rare diseases affecting the liver and eye, Generation Bio aims to overcome limitations of traditional gene therapy technologies. The company is positioned in the rapidly evolving biotechnology sector, highlighting its potential to influence the future of genomic medicine significantly.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
115
CEO
Ms. Yalonda Howze J.D.
Country
United States
IPO Year
2020
Website
generationbio.comGeneration Bio Co. (GBIO) Latest News & Analysis
Latest News
Quick Summary
Generation Bio Co. (Nasdaq: GBIO) reported its third quarter financial results on November 5, 2025.
Why It Matters
Generation Bio's Q3 financial results can influence investor sentiment, impacting stock performance and future funding prospects in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Generation Bio Announces CEO Transition
1 month ago
Quick Summary
Geoff McDonough will step down as CEO of Generation Bio Co. and become Chair of the Board. Yalonda Howze is named Interim CEO & President, effective October 22, 2025.
Why It Matters
Leadership changes can indicate shifts in strategy or stability, impacting investor confidence and stock performance. The appointment of an interim CEO raises questions about future direction and governance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Generation Bio Co. reported successful siRNA delivery to T cells using its ctLNP system in non-human primates. The company has $141.4M cash and is exploring strategic options to enhance shareholder value.
Why It Matters
New advancements in Generation Bio's delivery system could enhance treatments for autoimmune diseases, potentially increasing the company's value and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Generation Bio Co. (GBIO) reported a quarterly loss of $3.12 per share, exceeding the Zacks Consensus Estimate of a $2.8 loss, compared to a loss of $3.1 per share the previous year.
Why It Matters
Generation Bio's larger-than-expected quarterly loss raises concerns about its financial health and operational efficiency, potentially impacting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Generation Bio Co. (Nasdaq: GBIO) will execute a 1-for-10 reverse stock split on July 21, 2025, to increase its share price and maintain compliance with Nasdaq listing requirements.
Why It Matters
A 1-for-10 reverse stock split may improve Generation Bio's stock price, helping it meet Nasdaq listing requirements. Compliance affects liquidity and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Generation Bio Co. granted equity awards to a new employee on July 1, 2025, under its 2025 Inducement Stock Incentive Plan, in compliance with Nasdaq rules.
Why It Matters
Generation Bio's equity awards indicate growth potential and talent acquisition, which can enhance innovation and operational effectiveness, potentially impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GBIO Stock
What is Generation Bio Co.'s (GBIO) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Generation Bio Co. (GBIO) has a median price target of $10.00. The highest price target is $11.00 and the lowest is $7.00.
Is GBIO stock a good investment in 2026?
According to current analyst ratings, GBIO has 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GBIO stock?
Wall Street analysts predict GBIO stock could reach $10.00 in the next 12 months. This represents a 87.6% increase from the current price of $5.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Generation Bio Co.'s business model?
Generation Bio Co. operates by leveraging its innovative non-viral delivery platform to develop gene therapies aimed at treating various genetic disorders. The company generates revenue through partnerships, funding, and potentially by commercializing its gene therapy products as they advance through clinical development.
What is the highest forecasted price for GBIO Generation Bio Co.?
The highest price target for GBIO is $11.00 from David Nierengarten at Wedbush, which represents a 106.4% increase from the current price of $5.33.
What is the lowest forecasted price for GBIO Generation Bio Co.?
The lowest price target for GBIO is $7.00 from David Nierengarten at Wedbush, which represents a 31.3% increase from the current price of $5.33.
What is the overall GBIO consensus from analysts for Generation Bio Co.?
The overall analyst consensus for GBIO is neutral. Out of 7 Wall Street analysts, 2 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are GBIO stock price projections?
Stock price projections, including those for Generation Bio Co., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 8:09 AM UTC